Recursion director sells 30K shares under 10b5-1 plan

Recursion Pharmaceuticals director Blake Borgeson reported an open-market sale of Class A Common Stock.

Accepted by SEC EDGAR 04/08/2026 - 04:58 PM EDT

(Neutral)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Recursion Pharmaceuticals director Blake Borgeson reported an open-market sale of Class A Common Stock. On this transaction date, he sold 30,000 shares at a price of $3.10 per share. After the sale, he directly held 6,229,863 shares of Class A Common Stock.

The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted by Borgeson on August 31, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 30,000 shares

Net Sell 1 txn

Insider Borgeson Blake

Role Director

Sold 30,000 shs ($93K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	30,000	$3.10	$93K

Holdings After Transaction: Class A Common Stock — 6,229,863 shares (Direct)

Footnotes (1)

F1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.

Key Figures

Shares sold: 30,000 shares Sale price: $3.10 per share Shares held after sale: 6,229,863 shares

3 metrics

Shares sold 30,000 shares Open-market sale of Class A Common Stock

Sale price $3.10 per share Price for 30,000-share open-market sale

Shares held after sale 6,229,863 shares Direct Class A Common Stock ownership following transaction

Key Terms

Rule 10b5-1 trading plan, open-market sale, Class A Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"This transaction is pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Class A Common Stock financial

"security_title": "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RXRX director Blake Borgeson report?

Blake Borgeson reported selling 30,000 shares of Recursion Pharmaceuticals Class A Common Stock in an open-market transaction at $3.10 per share. This Form 4 filing shows a planned sale under a Rule 10b5-1 trading plan rather than a spontaneous trade.

At what price did Blake Borgeson sell RXRX Class A shares?

Borgeson sold his Recursion Pharmaceuticals Class A shares at $3.10 per share. The transaction involved 30,000 shares in an open-market sale, as disclosed in the Form 4, and was carried out under a previously adopted Rule 10b5-1 trading plan.

How many RXRX shares does Blake Borgeson hold after this sale?

After the disclosed sale, Borgeson directly holds 6,229,863 shares of Recursion Pharmaceuticals Class A Common Stock. The Form 4 shows this post-transaction balance, indicating he continues to maintain a substantial direct ownership position in the company following the 30,000-share sale.

Was Blake Borgeson’s RXRX stock sale under a Rule 10b5-1 plan?

Yes. The footnote explains the sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 31, 2025. Such plans allow insiders to pre-schedule trades, reducing the significance of trade timing as a signal of changing sentiment.

What type of security did Blake Borgeson sell in this RXRX Form 4?

The Form 4 shows Borgeson sold Class A Common Stock of Recursion Pharmaceuticals. It was a non-derivative open-market sale of 30,000 shares, and there were no accompanying derivative exercises or option-related transactions reported in this particular filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Borgeson Blake

(Last)

(First)

(Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY

UTAH

84101

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	04/07/2026		S⁽¹⁾		30,000	D	$3.1	6,229,863	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR